Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment

Experimental Neurology

Volumn 187, Issue 1, 2004, Pages 178-189

  Joyce, Jeffrey N ^a   Der, T C ^a,b   Renish, Lynn ^a   Osredkar, Tracy ^a   Hagner, Diane ^a   Reploge, Maria ^a   Sakakibara, Shinichi ^c   Ueda, Shuichi ^c  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

^c DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Nucleus accumbens; Parkinson's disease; Striatum; Substantia nigra; Tyrosine hydroxylase; Ventral tegmental area

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CARBIDOPA; DOPAMINE 3 RECEPTOR; DOPAMINE TRANSPORTER; LEVODOPA; TYROSINE 3 MONOOXYGENASE; ANTIPARKINSON AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CARRIER PROTEIN; DOPAMINE 2 RECEPTOR; DRD3 PROTEIN, RAT; MEMBRANE PROTEIN; MESSENGER RNA; NERVE PROTEIN; SLC6A3 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; CAUDATE NUCLEUS; CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; HETEROZYGOTE; MALE; MUTANT; NONHUMAN; OLFACTORY NERVOUS SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUTAMEN; RAT; STRIATONIGRAL DEGENERATION; ANIMAL; DISEASE COURSE; DISEASE MODEL; DRUG EFFECT; FOREBRAIN; GENETICS; HOMOZYGOTE; METABOLISM; NEOSTRIATUM; NUCLEUS ACCUMBENS; OLFACTORY SYSTEM; OXIDATIVE STRESS; PARKINSONISM; PATHOLOGY; PATHOPHYSIOLOGY; RAT STRAIN; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIPARKINSON AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HETEROZYGOTE; HOMOZYGOTE; ISLANDS OF CALLEJA; LEVODOPA; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NEOSTRIATUM; NERVE TISSUE PROTEINS; NUCLEUS ACCUMBENS; OLFACTORY PATHWAYS; OXIDATIVE STRESS; PARKINSONIAN DISORDERS; PROSENCEPHALON; RATS; RATS, MUTANT STRAINS; RATS, SPRAGUE-DAWLEY; RECEPTOR, TRKB; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RNA, MESSENGER; TYROSINE 3-MONOOXYGENASE;

EID: 1842663404     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2004.01.012     Document Type: Article

References (53)

1. Altar C.A., Cai N., Bliven T., Juhasz M., Conner J.M., Acheson A.L., Lindsay R.M., Wiegand S.J. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature. 389:1997;856-860.
2. Apaydin H., Ahlskog J.E., Parisi J.E., Boeve B.F., Dickson D.W. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch. Neurol. 59:2002;102-112.
3. Artymyshyn R., Smith A., Wolfe B.B. The use of 3H standards in 125I autoradiography. J. Neurosci. Methods. 32:1990;185-192.
4. Bézard E., Ferry S., Mach U., Stark H., Leriche L., Boraud T., Gross C., Sokoloff P. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat. Med. 9:2003;762-767.
5. Blunt S.B., Jenner P., Marsden C.D. Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov. Disord. 8:1993;129-133.
6. Bordet R., Ridray S., Carboni S., Diaz J., Sokoloff P., Schwartz J.C. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc. Natl. Acad. Sci. U.S.A. 94:1997;3363-3367.
7. Brooks D.J. Dopamine agonists: their role in the treatment of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 68:2000;685-689.
8. Caparros-Lefebvre D., Pecheux N., Petit V., Duhamel A., Petit H. Which factors predict cognitive decline in Parkinson's disease? J. Neurol. Neurosurg. Psychiatry. 58:1995;51-55.
9. Civelli O., Bunzow J.R., Grandy D.K. Molecular diversity of the dopamine receptors. Annu. Rev. Pharmacol. Toxicol. 33:1993;281-307.
10. Conner J.M., Lauterborn J.C., Yan Q., Gall C.M., Varon S. Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: evidence for anterograde axonal transport. J. Neurosci. 17:1997;2295-2313.
11. Fabbrini G., Mouradian M.M., Juncos J.L., Schlegel J., Mohr E., Chase T.N. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I. Ann. Neurol. 24:1988;366-371.
12. Gomi H., Ueno I., Yamanouchi K. Antioxidant enzymes in the brain of zitter rats: abnormal metabolism of oxygen species and its relevance to pathogenic changes in the brain of zitter rats with genetic spongiform encephalopathy. Brain Res. 653:1994;66-72.
13. Gross C.E., Ravenscroft P., Dovero S., Jaber M., Bioulac B., Bezard E. Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice. J. Neurochem. 84:2003;1246-1255.
14. Guillin O., Diaz J., Carroll P., Griffon N., Schwartz J.C., Sokoloff P. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature. 411:2001;86-89.
15. Gurevich E.V., Joyce J.N. Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology. 20:1999;60-80.
16. Gurevich E.V., Himes J.W., Joyce J.N. Developmental regulation of expression of the D3 dopamine receptor in rat nucleus accumbens and islands of Calleja. J. Pharmacol. Exp. Ther. 289:1999;587-598.
17. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology. 51:1998;S2-S9.
18. Hughes T.A., Ross H.F., Musa S., Bhattacherjee S., Nathan R.N., Mindham R.H., Spokes E.G. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology. 54:2000;1596-1602.
19. Hurtig H.I., Trojanowski J.Q., Galvin J., Ewbank D., Schmidt M.L., Lee V.M., Clark C.M., Glosser G., Stern M.B., Gollomp S.M., Arnold S.E. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology. 54:2000;1916-1921.
20. Isackson P.J., Huntsman M.M., Murray K.D., Gall C.M. BDNF mRNA expression is increased in adult rat forebrain after limbic seizures: temporal patterns of induction distinct from NGF. Neuron. 6:1991;937-948.
21. Jellinger K.A. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol. Chem. Neuropathol. 14:1991;153-197.
22. Joyce J.N. Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine: I. Effects of intranigral or intracerebroventricular 6-hydroxydopamine lesions of the mesostriatal dopamine system. Exp. Neurol. 113:1991;261-276.
23. 3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period. Synapse. 40:2001;137-144.
24. 3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol. Ther. 90:2001;231-259.
25. Joyce J.N., Marshall J.F., Bankiewicz K.S., Kopin I.J., Jacobowitz D.M. Hemiparkinsonism in a monkey after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is associated with regional ipsilateral changes in striatal dopamine D-2 receptor density. Brain Res. 382:1986;360-364.
26. 3 receptors with degeneration of the dopamine system. NeuroReport. 11:2000;2173-2175.
27. Joyce J.N., Ryoo H.L., Beach T.B., Caviness J.N., Stacy M., Gurevich E.V., Reiser M., Adler C.H. Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors. Brain Res. 955:2002;138-152.
28. Joyce J.N., Presgraves S., Renish L., Borwege S., Hagner D., Osredkar T., Replogle M., Paz Soldán M.M., Millan M.J. Neuroprotective effects of the novel D3/D2 receptor agonist and anitparkinson agent S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl- 4-phenyl-1,2,2,6-tetrahydropyridine (MPTP): a comparison to ropinirole. Exp. Neurol. 184:2003;393-407.
29. Joyce J.N., Renish L., Osredkar T., Walro J.M., Kucera J., Dluzen D.E. Methamphetamine induced loss of striatal dopamine innervation in BNDF heterozygote mice does not further alter D3 receptor concentrations. Synapse. 52:2004;11-19.
30. Klein R., Conway D., Parada L.F., Barbacid M. The trkB tyrosine protein kinase gene codes for a second neurogenic receptor that lacks the catalytic kinase domain. Cell. 61:1990;647-656.
31. Kondo A., Sendoh S., Miyata K., Takamatsu J. Spongy degeneration in the zitter rat: ultrastructural and immunohistochemical studies. J. Neurocytol. 24:1995;533-544.
32. Lai C.T., Yu P.H. Dopamine- and L-beta-3,4-dihydroxyphenylalanine hydrochloride (L-dopa)- induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Effects of oxidative stress and antioxidative factors. Biochem. Pharmacol. 53:1997;363-372.
33. Lévesque D., Martres M.P., Diaz J., Griffon N., Lammers C.H., Sokoloff P., Schwartz J.C. A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc. Natl. Acad. Sci. U.S.A. 92:1995;1719-1723.
34. Marder K., Tang M.X., Cote L., Stern Y., Mayeux R. The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch. Neurol. 52:1995;695-701.
35. Mattila P.M., Rinne J.O., Helenius H., Dickson D.W., Roytta M. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol. (Berl.). 100:2000;285-290.
36. McRitchie D.A., Cartwright H.R., Halliday G.M. Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease. Exp. Neurol. 144:1997;202-213.
37. Morissette M., Goulet M., Grondin R., Blanchet P., Bedard P.J., Di Paolo T., Levesque D. Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies. Eur. J. Neurosci. 10:1998;2565-2573.
38. Mouradian M.M., Juncos J.L., Fabbrini G., Schlegel J., Bartko J.J., Chase T.N. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II. Ann. Neurol. 24:1988;372-378.
39. Murer M.G., Dziewczapolski G., Menalled L.B., Garcia M.C., Agid Y., Gershanik O., Raisman-Vozari R. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann. Neurol. 43:1998;561-575.
40. Murray A.M., Weihmueller F.B., Marshall J.F., Hurtig H.I., Gottleib G.L., Joyce J.N. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism. Ann. Neurol. 37:1995;300-312.
41. Muto Y., Hayashi T., Higashi Y., Endo T., Yamamoto T., Sato K. Age-related decrease in brain-derived neurotrophic factor gene expression in the brain of the zitter rat with genetic spongiform encephalopathy. Neurosci. Lett. 271:1999;69-72.
42. Naudin B., Bonnet J.J., Costentin J. Acute L-DOPA pretreatment potentiates 6-hydroxydopamine-induced toxic effects on nigro-striatal dopamine neurons in mice. Brain Res. 701:1995;151-157.
43. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic Press, Sydney Australia.
44. Pizzolato G., Chierichetti F., Rossato A., Cagnin A., Fabbri M., Dam M., Ferlin G., Battistin L. Alterations of striatal dopamine D2 receptors contribute to deteriorated response to L-dopa in Parkinson's disease: a [123I]-IBZM SPET study. J. Neural. Transm., Suppl. 45:1995;113-122.
45. Portin R., Rinne U.K. Predictive factors for cognitive deterioration and dementia in Parkinson's disease. Adv. Neurol. 45:1987;413-416.
46. Quik M., Police S., He L., Di Monte D.A., Langston J.W. Expression of D3 receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment. Neuroscience. 98:2000;263-273.
47. 2 receptor is elevated in the striatum of Parkinson's disease. Mov. Disord. 13:1998;788-797.
48. Spencer J.P., Jenner P., Halliwell B. Superoxide-dependent depletion of reduced glutathione by L-DOPA and dopamine. Relevance to Parkinson's disease. NeuroReport. 6:1995;1480-1484.
49. Stern Y., Marder K., Tang M.X., Mayeux R. Antecedent clinical features associated with dementia in Parkinson's disease. Neurology. 43:1993;1690-1692.
50. Ueda S., Aikawa M., Ishizuya-Oka A., Koibuchi N., Yamaoka S., Yoshimoto K. Age-related degeneration of the serotoninergic fibers in the zitter rat brain. Synapse. 30:1998;62-70.
51. Ueda S., Aikawa M., Ishizuya-Oka A., Yamaoka S., Koibuchi N., Yoshimoto K. Age-related dopamine deficiency in the mesostriatal dopamine system of zitter mutant rats: regional fiber vulnerability in the striatum and the olfactory tubercle. Neuroscience. 95:2000;389-398.
52. Ueda S., Sakakibara S., Watanabe E., Yoshimoto K., Koibuchi N. Vulnerability of monoaminergic neurons in the brainstem of the zitter rat in oxidative stress. Prog. Brain Res. 136:2002;293-302.
53. Wade T.V., Rothblat D.S., Schneider J.S. Changes in striatal dopamine D3 receptor regulation during expression of and recovery from MPTP-induced parkinsonism. Brain Res. 905:2001;111-119.